| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1aa7e110cbb462ee0d1b074fd83895d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3239872c88dbe0f8d1d70ca97234ae0c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-224
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-222
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-226
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70564 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56966 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2017-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ab77c8aba37e8ad45f325d77c64cd7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55ad948f9249a40cb36c21cb10174cd9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7dff2f4bf556df1d97b8d2fa62f4722b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ac646ad31b13caf59adc3b55f8472e8 |
| publicationDate |
2019-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10215767-B2 |
| titleOfInvention |
Method of detecting platelet activating antibodies that cause heparin-induced thrombocytopenia/thrombosis |
| abstract |
The present invention provides a method of detecting platelet activation in a patient, the method comprising the steps of a) obtaining a blood sample from a patient suspected of having heparin-induced thrombocytopenia (HIT); b) incubating an effective amount of platelet factor 4 (PF4) with a sample of platelets to yield a sample of PF4-treated platelets; c) contacting the patient blood sample with the PF4-treated platelets; and d) measuring the extent of platelet activation, wherein an increase in platelet activation compared with results obtained using a normal blood sample is indicative of the patient having HIT. |
| priorityDate |
2013-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |